Volume 46, Number 1, July 1, 1999

EDITORIALS

1 **Increasing Public Trust and Confidence in Psychiatric Research**
Dennis S. Charney, Robert B. Innis, Eric J. Nestler, Kenneth L. Davis, Charles B. Nemeroff, and Daniel R. Weinberger

3 **Schizophrenia Research Series: From Molecule to Public Policy**
Carol A. Tamminga and Jeffrey A. Lieberman

3 **Schizophrenia: New Phenes and New Genes**
Daniel R. Weinberger

SCHIZOPHRENIA RESEARCH SERIES: NEURODEVELOPMENT AND PATHOPHYSIOLOGY

8 **Elementary Phenotypes in the Neurobiological and Genetic Study of Schizophrenia**
Lawrence E. Adler, Robert Freedman, Randal G. Ross, Ann Olincy, and Merilyne C. Waldo

19 **Forebrain Induction, Retinoic Acid, and Vulnerability to Schizophrenia: Insights from Molecular and Genetic Analysis in Developing Mice**
Anthony-Samuel LaMantia

31 **The Neurodevelopmental Basis of Schizophrenia: Clinical Clues from Cerebro-Craniofacial Dysmorphogenesis, and the Roots of a Lifetime Trajectory of Disease**
John L. Waddington, Abbie Lane, Conall Larkin, and Eadbhard O'Callaghan

40 **The Regulation of Forebrain Dopamine Transmission: Relevance to the Pathophysiology and Psychopathology of Schizophrenia**
Holly Moore, Anthony R. West, and Anthony A. Grace

56 **Increased Dopamine Transmission in Schizophrenia: Relationship to Illness Phases**
Marc Laruelle, Anissa Abi-Dargham, Roberto Gil, Lawrence Kegeles, and Robert Innis

ORIGINAL ARTICLES

73 **Treatment-Resistant Schizophrenic Patients Respond to Clozapine after Olanzapine Non-Response**
Robert R. Conley, Carol A. Tamminga, Deanna L. Kelly, and Charles M. Richardson

78 **An MRI Study of Adolescent Patients with Either Schizophrenia or Bipolar Disorder as Compared to Healthy Control Subjects**
Lee Friedman, Robert L. Findling, John T. Kenny, Thomas P. Swales, Traci A. Stuve, John A. Jesberger, Jonathan S. Lewin, and S. Charles Schulz

89 **SPECT Study of Visual Fixation in Schizophrenia and Comparison Subjects**
Dolores Malaspina, Stephen Storer, Vitaly Furman, Peter Esser, David Printz, Ariela Berman, Angela Lignelli, Jack Gorman, and Ronald Van Heertum

94 **P300 Amplitude is Related to Clinical State in Severely and Moderately Ill Patients with Schizophrenia**
Judith M. Ford, Daniel H. Mathalon, Laura Marsh, William O. Faustman, Debra Harris, Anne L. Hoff, Michael Beal, and Adolf Pfefferbaum

102 **Relationship between Nailfold Plexus Visibility and Clinical, Neuropsychological, and Brain Structural Measures in Schizophrenia**
Clayton E. Curtis, William G. Iacono, and Morton Beiser

110 **Elevation of $CD5^+$ B Lymphocytes in Schizophrenia**
David J. Printz, David H. Strauss, Raymond Goetz, Saud Sadiq, Dolores Malaspina, John Krolewski, and Jack M. Gorman

119 **Schizophrenia and the Influenza Epidemics of 1957 in Japan**
Yuji Izumoto, Shimpei Inoue, and Nobufumi Yasuda

125 **Smoking and Therapeutic Response to Clozapine in Patients with Schizophrenia**
Joseph P. McEvoy, Oliver Freudenreich, and William H. Wilson

BRIEF REPORTS

130 **Transcranial Magnetic Stimulation of Left Temporoparietal Cortex in Three Patients Reporting Hallucinated "Voices"**
Ralph E. Hoffman, Nashaat N. Boutros, Robert M. Berman, Elizabeth Roessler, Aysenil Belger, John H. Krystal, and Dennis S. Charney

133 **Schizoaffective Disorder: Evidence for Reversed Cerebral Asymmetry**
Martin Reite, Peter Teale, Donald C. Rojas, Jeanelle Sheeder, and David Arciniegas

137 **Lack of Repetition Priming Effect on Visual Event-Related Potentials in Schizophrenia**
Hiroo Matsuoka, Kazunori Matsumoto, Hisato Yamazaki, Hirotaka Sakai, Shinya Miwa, Sumiko Yoshida, Yohtaro Numachi, Hidemitsu Saito, Takashi Ueno, and Mitsumoto Sato

141 **Olanzapine Acute Administration in Schizophrenic Patients Increases Delta Sleep and Sleep Efficiency**
Rafael J. Salin-Pascual, Miguel Herrera-Estrella, Lourdes Galicia-Polo, and Martha Rosas Laurrabaquio

CORRESPONDENCE

144 **Dopamine$_2$ Receptor Occupancy and the Action of Clozapine: Does it Make a Difference to Add a Neuroleptic?**
Herbert Y. Meltzer

Volume 46, Number 2, July 15, 1999

PRIORITY COMMUNICATIONS

151 **Global Variation of a 40-bp VNTR in the 3′-Untranslated Region of the Dopamine Transporter Gene (SLC6A3)**
A. Min Kang, Meg A. Palmatier, and Kenneth K. Kidd

161 **Increased Volume and Glial Density in Primate Prefrontal Cortex Associated with Chronic Antipsychotic Drug Exposure**
Lynn D. Selemon, Michael S. Lidow, and Patricia S. Goldman-Rakic

ORIGINAL ARTICLES

173 **Clinical and Neurobiological Correlates of DXS1047 Genotype in Alzheimer's Disease**
George S. Zubenko, Hugh B. Hughes, and J. Scott Stiffler

182 **Estrogen Replacement Therapy and Cognitive Decline in Memory-Impaired Post-Menopausal Women**
M. Martin Costa, Victor I. Reus, Owen M. Wolkowitz, Francesca Manfredi, and Morton Lieberman

189 **Physostigmine Challenge before and after Chronic Cholinergic Blockade in Elderly Volunteers**
Ruth Dukoff, Charles W. Wilkinson, Robert Lasser, Judy Friz, Anne Conway, Marcel Bahro, Elaine R. Peskind, and Trey Sunderland

196 **Frequency of Long Allele in Serotonin Transporter Gene Is Increased in Depressed Suicide Victims**
Lisheng Du, Gábor Faludi, Miklós Palkovits, Elizabeth Demeter, David Bakish, Yvon D. Lapierre, Peter Sótonyi, and Pavel D. Hrdina

202 **Patterns of Axis I Comorbidity in Early-Onset Versus Late-Onset Major Depressive Disorder**
Jonathan E. Alpert, Maurizio Fava, Lisa A. Uebelacker, Andrew A. Nierenberg, Joel A. Pava, John J. Worthington III, and Jerrold F. Rosenbaum

212 **Tryptophan-Depletion Challenge in Depressed Patients Treated with Desipramine or Fluoxetine: Implications for the Role of Serotonin in the Mechanism of Antidepressant Action**
Pedro L. Delgado, Helen L. Miller, Ronald M. Salomon, Julio Licinio, John H. Krystal, Francisco A. Moreno, George R. Heninger, and Dennis S. Charney

221 **Biogenic Amine Activity in Response to Fluoxetine and Desipramine in Differentially Reared Rhesus Monkeys**
A. Susan Clarke, Michael H. Ebert, Dennis E. Schmidt, William T. McKinney, and Gary W. Kraemer

229 **The Effect of Acute Tryptophan Depletion and Fenfluramine on Quantitative EEG and Mood in Healthy Male Subjects**
Verner J. Knott, Anne L. Howson, Mary Perugini, Arun V. Ravindran, and Simon N. Young

239 **Prophylactic Treatment of Seasonal Affective Disorder (SAD) by Using Light Visors: Bright White or Infrared Light?**
Ybe Meesters, Domien G.M. Beersma, Antoinette L. Bouhuys, and Rutger H. van den Hoofdakker

247 **Elevated Basal and Thapsigargin-Stimulated Intracellular Calcium of Platelets and Lymphocytes from Bipolar Affective Disorder Patients Measured by a Fluorometric Microassay**
Christopher Hough, Sha-Jia Lu, Candace L. Davis, De-Maw Chuang, and Robert M. Post

256 **Consequences of Deterministic and Random Dynamics for the Course of Affective Disorders**
Martin T. Huber, Hans A. Braun, and Jürgen C. Krieg

263 **P300 Decrements in Teenagers with Conduct Problems: Implications for Substance Abuse Risk and Brain Development**
Lance O. Bauer and Victor M. Hesselbrock

273 **Laboratory and Psychometric Measurements of Impulsivity Among Violent and Nonviolent Female Parolees**
Don R. Cherek and Scott D. Lane

281 **Visual P3a in Male Subjects at High Risk for Alcoholism**
Socorro Rodríguez Holguín, Bernice Porjesz, David B. Chorlian, John Polich, and Henri Begleiter

292 **Leptin, Neuropeptide Y, and Peptide YY in Long-Term Recovered Eating Disorder Patients**
Kelly A. Gendall, Walter H. Kaye, Margaret Altemus, Claire W. McConaha, and Maria C. La Via

Volume 46, Number 3, August 1, 1999

EDITORIAL

301 **Neuroscience and Schizophrenia**
Carol A. Tamminga

SCHIZOPHRENIA RESEARCH SERIES: PATHOPHYSIOLOGY AND TREATMENT

303 **Functional Hyperdopaminergia in Dopamine Transporter Knock-Out Mice**
Raul R. Gainetdinov, Sara R. Jones, and Marc G. Caron

312 **Cognition and Control in Schizophrenia: A Computational Model of Dopamine and Prefrontal Function**
Todd S. Braver, Deanna M. Barch, and Jonathan D. Cohen

329 **Memory and Socioemotional Behavior in Monkeys after Hippocampal Damage Incurred in Infancy or in Adulthood**
Jocelyne Bachevalier, Maria C. Alvarado, and Ludise Malkova

340 **Does Neurotensin Mediate the Effects of Antipsychotic Drugs?**
Becky Kinkead, Elisabeth B. Binder, and Charles B. Nemeroff

352 **Deficit Psychopathology and a Paradigm Shift in Schizophrenia Research**
William T. Carpenter Jr., Celso Arango, Robert W. Buchanan, and Brian Kirkpatrick

361 **The Psychosis of Schizophrenia: Prevalence, Response to Atypical Antipsychotics, and Prediction of Outcome**
Alan Breier and Paul H. Berg

365 **The Course of Depressive Symptoms in Predicting Relapse in Schizophrenia: A Double-Blind, Randomized Comparison of Olanzapine and Risperidone**
Gary D. Tollefson, Scott W. Andersen, and Pierre V. Tran

ORIGINAL ARTICLES

374 **Cumulative Effect of Anatomical Risk Factors for Schizophrenia: An MRI Study**
Christiana M. Leonard, John M. Kuldau, Joshua I. Breier, Paula A. Zuffante, Erin R. Gautier, Dawn-Christy Heron, Elise M. Lavery, Jennifer Packing, Sharyl A. Williams, and Cheryl A. DeBose

383 **The Effects of Age on a Smooth Pursuit Tracking Task in Adults with Schizophrenia and Normal Subjects**
Randal G. Ross, Ann Olincy, Josette G. Harris, Allen Radant, Lawrence E. Adler, Nina Compagnon, and Robert Freedman

392 **Spatial Working Memory Deficits and Clinical Symptoms in Schizophrenia: A 4-Month Follow-Up Study**
Sohee Park, Jörg Püschel, Barbara H. Sauter, Markus Rentsch, and Daniel Hell

401 **Clinical Subtyping Reveals Significant Differences in Calcium-Dependent Phospholipase A_2 Activity in Schizophrenia**
Craig Hudson, Andrew Gotowiec, Mary Seeman, Jerry Warsh, and Brian M. Ross

406 **Neither Short-Term Nor Long-Term Administration of Oral Choline Alters Metabolite Concentrations in Human Brain**
Peter Dechent, Petra J.W. Pouwels, and Jens Frahm

412 **Physiologic and Neuroendocrine Responses to Intravenous Naloxone in Subjects with Alzheimer's Disease and Age-Matched Controls**
Pierre N. Tariot, Ajaya Upadhyaya, Trey Sunderland, Christopher Cox, Robert M. Cohen, Dennis L. Murphy, and Rebekah Loy

420 **Sulphation Deficit in "Low-Functioning" Autistic Children: A Pilot Study**
Antonino Alberti, Patrizia Pirrone, Maurizio Elia, Rosemary H. Waring, and Corrado Romano

425 **Cognitive Impairment and (CTG)n Expansion in Myotonic Dystrophy Patients**
Giulia I. Perini, Elisabetta Menegazzo, Mario Ermani, Michele Zara, Andrea Gemma, Emilia Ferruzza, Massimo Gennarelli, and Corrado Angelini

432 **Sodium Valproate Increases Pupillary Responsiveness to a Cholinergic Agonist in Responders with Mania**
Edward M. DeMet and Kenneth N. Sokolski

437 **A Double-Blind Comparison of Lorazepam and Oxazepam in Psychomotor Retardation and Mutism**
Jürgen Schmider, Harald Standhart, Michael Deuschle, Jutta Drancoli, and Isabella Heuser

CASE REPORT

442 **Yohimbine Use in a Natural Setting: Effects on Posttraumatic Stress Disorder**
Steven M. Southwick, Charles A. Morgan, III, Dennis S. Charney, and James R. High

Volume 46, Number 4, August 15, 1999

REVIEW

445 **Sleep Deprivation in Depression: What Do We Know, Where Do We Go?**
Anna Wirz-Justice and Rutger H. Van den Hoofdakker

ORIGINAL ARTICLES

454 **Regional Brain Activity during Transient Self-Induced Anxiety and Anger in Healthy Adults**
Tim A. Kimbrell, Mark S. George, Priti I. Parekh, Terence A. Ketter, Daniel M. Podell, Aimee L. Danielson, Jennifer D. Repella, Brenda E. Benson, Mark W. Willis, Peter Herscovitch, and Robert M. Post

466 **Anger in Healthy Men: A PET Study Using Script-Driven Imagery**
Darin D. Dougherty, Lisa M. Shin, Nathaniel M. Alpert, Roger K. Pitman, Scott P. Orr, Mark Lasko, Mike L. Macklin, Alan J. Fischman, and Scott L. Rauch

473 **Morphometry of the Dorsal Raphe Nucleus Serotonergic Neurons in Suicide Victims**
Mark D. Underwood, Alfia A. Khaibulina, Steven P. Ellis, Andrew Moran, Patricia M. Rice, J. John Mann, and Victoria Arango

484 **Decreased Platelet Peripheral-Type Benzodiazepine Receptors in Adolescent Inpatients with Repeated Suicide Attempts**
Noam Soreni, Alan Apter, Abraham Weizman, Ofri Don-Tufeled, Svetlana Leschiner, Leon Karp, and Moshe Gavish

489 **Mood Effects of 24-Hour Tryptophan Depletion in Healthy First-Degree Relatives of Patients with Affective Disorders**
Tineke Klaassen, Wim J. Riedel, Astrid van Someren, Nicolaas E.P. Deutz, Adriaan Honig, and Herman M. van Praag

498 **Tryptophan Depletion and Depressive Vulnerability**
Francisco A. Moreno, Alan J. Gelenberg, George R. Heninger, Rebecca L. Potter, Katherine M. McKnight, John Allen, Aleksandra P. Phillips, and Pedro L. Delgado

506 **Prolactin Secretion in Depressed Children**
Antonio Hardan, Boris Birmaher, Doug E. Williamson, Ronald E. Dahl, Paul Ambrosini, Harris Rabinovich, and Neal D. Ryan

512 **The Influence of Prolactin Response to *d*-Fenfluramine on Executive Functioning in Major Depression**
Alessio Degl'Innocenti, Hans Ågren, Olof Zachrisson, and Lars Bäckman

518 **Pretreatment Platelet 5-HT Concentration Predicts the Short-Term Response to Paroxetine in Major Depression**
Gloria Figueras, Victor Pérez, Olga San Martino, Enrique Alvarez, Grupo de Trastornos Afectivos, and Francesc Artigas

525 **Declarative and Procedural Memory in Bipolar Disorder**
Wilfred G. van Gorp, Lori Altshuler, David C. Theberge, and Jim Mintz

532 **Serum Cholesterol, Suicidal Tendencies, Impulsivity, Aggression, and Depression in Adolescent Psychiatric Inpatients**
Alan Apter, Neil Laufer, Michal Bar-Sever, Dov Har-Even, Hadas Ofek, and Abraham Weizman

542 **Affective Startle Modulation in Clinical Depression: Preliminary Findings**
Nicholas B. Allen, John Trinder, and Catherine Brennan

557 **Global Variation in the Frequencies of Functionally Different Catechol-*O*-Methyltransferase Alleles**
Meg A. Palmatier, A. Min Kang, and Kenneth K. Kidd

TECHNIQUES AND METHODS

568 **Salivary Prolactin as a Marker for Central Serotonin Turnover**
Stephen G. Lindell, Stephen J. Suomi, Susan Shoaf, Markku Linnoila, and J. Dee Higley

BRIEF REPORTS

573 **Effects of Catecholamine Depletion with AMPT (alpha-methyl-para-tyrosine) in Obsessive-Compulsive Disorder**
James G. Longhurst, Linda L. Carpenter, C. Neill Epperson, Lawrence H. Price, and Christopher J. McDougle

577 **Lack of Relationship between Menstrual Cycle Phase and Mood in a Sample of Women with Rapid Cycling Bipolar Disorder**
Ellen Leibenluft, Sharon B. Ashman, Susana Feldman-Naim, and Kimberly A. Yonkers

581 **Neuroendocrine Evidence for Dopaminergic Actions of Hypericum Extract (LI 160) in Healthy Volunteers**
Mike Franklin, Jingduan Chi, Cameron McGavin, Rena Hockney, Alison Reed, Gillian Campling, Richard W.R. Whale, and Phillip J. Cowen

585 **Erratum**

Volume 46, Number 5, September 1, 1999

EDITORIAL

587 **Schizophrenia as a Neuronal Illness**
Robert Freedman

SCHIZOPHRENIA RESEARCH SERIES: NEUROBIOLOGY

589 **Evidence for Altered Trisynaptic Circuitry in Schizophrenic Hippocampus**
Francine M. Benes

600 **Neurochemical Brain Imaging Investigations of Schizophrenia**
Jair C. Soares and Robert B. Innis

616 **Altered GABA Neurotransmission and Prefrontal Cortical Dysfunction in Schizophrenia**
David A. Lewis, Joseph N. Pierri, David W. Volk, Darlene S. Melchitzky, and Tsung-Ung W. Woo

627 **Structural Brain Imaging in Schizophrenia: A Selective Review**
Godfrey D. Pearlson and Laura Marsh

650 **The Physiological Approach: Functional Architecture of Working Memory and Disordered Cognition in Schizophrenia**
Patricia S. Goldman-Rakic

662 **The Nonlinear, Complex Sequential Organization of Behavior in Schizophrenic Patients: Neurocognitive Strategies and Clinical Correlations**
Martin P. Paulus, William Perry, and David L. Braff

ORIGINAL ARTICLES

671 **Pursuit Tracking Impairments in Schizophrenia and Mood Disorders: Step-Ramp Studies with Unmedicated Patients**
John A. Sweeney, Beatriz Luna, Gretchen L. Haas, Matcheri S. Keshavan, J. John Mann, and Michael E. Thase

681 **Increased Dopamine Synthesis Rate in Medial Prefrontal Cortex and Striatum in Schizophrenia Indicated by L-(β-^{11}C) DOPA and PET**
Leif H. Lindström, Ola Gefvert, Gisela Hagberg, Tommie Lundberg, Mats Bergström, Per Hartvig, and Bengt Långström

689 **Mitogen-Activated Protein Kinases in Schizophrenia**
Svetlana V. Kyosseva, Alan D. Elbein, W. Sue T. Griffin, Robert E. Mrak, Melvin Lyon, and Craig N. Karson

697 **Hippocampal Volume Reduction in Schizophrenia: Effects of Genetic Risk and Pregnancy and Birth Complications**
Nick Stefanis, Sophia Frangou, Jessica Yakeley, Tonmoy Sharma, Paul O'Connell, Kevin Morgan, Thordur Sigmudsson, Mark Taylor, and Robin Murray

703 **An MRI Study of Cerebellar Vermis Morphology in Patients with Schizophrenia: Evidence in Support of the Cognitive Dysmetria Concept**
Peg C. Nopoulos, John W. Ceilley, Elizabeth A. Gailis, and Nancy C. Andreasen

712 **Caudate Size in First-Episode Neuroleptic-Naive Schizophrenic Patients Measured Using an Artificial Neural Network**
Patricia Westmoreland Corson, Peg Nopoulos, Nancy C. Andreasen, Dan Heckel, and Stephan Arndt

721 **Genetic Influence on Auditory Information Processing in Schizophrenia: P300 in Monozygotic Twins**
Matthias Weisbrod, Holger Hill, Rainer Niethammer, and Heinrich Sauer

Volume 46, Number 6, September 15, 1999

EDITORIAL

727 **Protecting Research Subjects and Psychiatric Research: We Can Do Both**
Kenneth L. Davis, David L. Braff, and Daniel R. Weinberger

REVIEW

729 **Is Schizophrenia a Neurodegenerative Disorder? A Clinical and Neurobiological Perspective**
Jeffrey A. Lieberman

ORIGINAL ARTICLES

740 **Clinical and Neurobiological Correlates of D10S1423 Genotype in Alzheimer's Disease**
George S. Zubenko, Hugh B. Hughes, III, and J. Scott Stiffler

750 **Longitudinal Stability of CSF Tau Levels in Alzheimer Patients**
Trey Sunderland, Benjamin Wolozin, Douglas Galasko, James Levy, Ruth Dukoff, Marcel Bahro, Robert Lasser, Ruth Motter, Terho Lehtimäki, and Peter Seubert

756 **Patterns of Cerebrospinal Fluid Catechols Support Increased Central Noradrenergic Responsiveness in Aging and Alzheimer's Disease**
Murray A. Raskind, Elaine R. Peskind, Courtney Holmes, and David S. Goldstein

766 **Locus Coeruleus Neuronal Activity and Noradrenaline Availability in the Frontal Cortex of Rats Chronically Treated with Imipramine: Effect of α_2-adrenoceptor Blockade**
Love Linnér, Lotta Arborelius, George G. Nomikos, Leif Bertilsson, and Torgny H. Svensson

775 **Antibodies against a Neuron-Like (HTB-10 Neuroblastoma) Cell in Children with Tourette Syndrome**
Harvey S. Singer, Joseph D. Giuliano, Bendt H. Hansen, Joseph J. Hallett, Joseph P. Laurino, Margaret Benson, and Louise S. Kiessling

781 **ERP Differences among Subtypes of Pervasive Developmental Disorders**
Chantal Kemner, Rutger Jan van der Gaag, Marinus Verbaten, and Herman van Engeland

790 **Platelet Dense Granule Secretion and Aggregation in Adolescents with Conduct Disorder: Effects of Marijuana Use**
Howard B. Moss, Jeffrey K. Yao, and Kevin Lynch

799 **Cardiac Adaptivity to Attention-Demanding Tasks in Children with a Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)**
Monika Althaus, Lambertus J.M. Mulder, Gijsbertus Mulder, Cecilia C. Aarnoudse, and Ruud B. Minderaa

810 **Immunological Alterations in Adult Obsessive-Compulsive Disorder**
Donatella Marazziti, Silvio Presta, Chiara Pfanner, Alfredo Gemignani, Alessandra Rossi, Silverio Sbrana, Valeria Rocchi, Fabio Ambrogi, and Giovanni B. Cassano

815 **A Segregation Study of Panic Disorder in Families of Panic Patients Responsive to the 35% CO2 Challenge**
Maria Cristina Cavallini, Giampaolo Perna, Daniela Caldirola, and Laura Bellodi

821 **HTR2C Cys23Ser Polymorphism in Relation to CSF Monoamine Metabolite Concentrations and DSM-III-R Psychiatric Diagnoses**
Jaakko Lappalainen, Jeffrey C. Long, Matti Virkkunen, Norio Ozaki, David Goldman, and Markku Linnoila

827 **Suppression of Melatonin by 2000-Lux Light in Humans with Closed Eyelids**
Taina Hätönen, Aino Alila-Johansson, Satu Mustanoja, and Maija-Liisa Laakso

832 **Involvement of Serotonin 2A Receptors in Phencyclidine-Induced Disruption of Prepulse Inhibition of the Acoustic Startle in Rats**
Shigeto Yamada, Mutsuo Harano, Naoko Annoh, Kaoru Nakamura, and Masatoshi Tanaka

839 **Citalopram and Desmethylcitalopram In Vitro: Human Cytochromes Mediating Transformation, and Cytochrome Inhibitory Effects**
Lisa L. von Moltke, David J. Greenblatt, Jeffrey M. Grassi, Brian W. Granda, Karthik Venkatakrishnan, Su Xiang Duan, Steven M. Fogelman, Jerold S. Harmatz, and Richard I. Shader

850 **Salivary Cortisol and Serum Prolactin in Relation to Stress Rating Scales in a Group of Rescue Workers**
Elisabeth Aardal-Eriksson, Thomas Erik Eriksson, Ann-Charlotte Holm, and Tom Lundin

BRIEF REPORTS

856 **Late-Onset Congenital Adrenal Hyperplasia: A Treatable Cause of Anxiety**
Alan R. Jacobs, Phyllis B. Edelheit, Anton E. Coleman, and Andrew G. Herzog

860 **Placebo-Controlled Trial of the CCK-B Antagonist, CI-988, in Panic Disorder**
Atul C. Pande, Martha Greiner, Judith Bammert Adams, R. Bruce Lydiard, and Mark W. Pierce

CASE REPORT

863 **Bilateral Globus Pallidus Lesions in a Patient with Tourette Syndrome and Related Disorders**
Aydin Demirkol, Hacer Erdem, Levent Inan, Aytac Yigit, and Melike Güney

Volume 46, Number 7, October 1, 1999

EDITORIAL

869 **Schizophrenia: Comments on Genes, Development, Risk Factors, Phenotype, and Course**
Jeffrey A. Lieberman

SCHIZOPHRENIA RESEARCH SERIES: PHENOMENOLOGY AND PATHOPHYSIOLOGY

871 **Epidemiology and Natural History of Schizophrenia**
Evelyn J. Bromet and Shmuel Fennig

882 **22q11 Deletion Syndrome: A Genetic Subtype of Schizophrenia**
Anne S. Bassett and Eva W.C. Chow

892 **Childhood-Onset Schizophrenia: Progressive Brain Changes during Adolescence**
Jay N. Giedd, Neal O. Jeffries, Jonathan Blumenthal, F.X. Castellanos, Anna C. Vaituzis, Thomas Fernandez, Susan D. Hamburger, Hong Liu, Jean Nelson, Jeff Bedwell, Lan Tran, Marge Lenane, Rob Nicolson, and Judith L. Rapoport

899 **Duration of Untreated Psychosis in First-Episode Schizophrenia: Marker or Determinant of Course?**
Thomas H. McGlashan

908 **Defining the Phenotype of Schizophrenia: Cognitive Dysmetria and Its Neural Mechanisms**
Nancy C. Andreasen, Peg Nopoulos, Daniel S. O'Leary, Del D. Miller, Thomas Wassink, and Michael Flaum

921 **Cognitive and Functional Changes with Aging in Schizophrenia**
Joseph I. Friedman, Philip D. Harvey, Eileen Kemether, William Byne, and Kenneth L. Davis

REVIEW

929 **Lithium at 50: Have the Neuroprotective Effects of This Unique Cation Been Overlooked?**
Husseini K. Manji, Gregory J. Moore, and Guang Chen

ORIGINAL ARTICLES

941 **Thalamic and Amygdala–Hippocampal Volume Reductions in First-Degree Relatives of Patients with Schizophrenia: An MRI-Based Morphometric Analysis**
Larry J. Seidman, Stephen V. Faraone, Jill M. Goldstein, Julie M. Goodman, William S. Kremen, Rosemary Toomey, Jason Tourville, David Kennedy, Nikos Makris, Verne S. Caviness, and Ming T. Tsuang

955 **Superior Temporal Gyral Volumes and Laterality Correlates of Auditory Hallucinations in Schizophrenia**
Charlene Levitan, Philip B. Ward, and Stanley V. Catts

963 **Eye Movements Reflect Impaired Face Processing in Patients with Schizophrenia**
Barry R. Manor, Evian Gordon, Leanne M. Williams, Chris J. Rennie, Homayoun Bahramali, Cyril R. Latimer, Robert J. Barry, and Russell A. Meares

970 **Developmental Delay in P300 Production in Children at High Risk for Developing Alcohol-Related Disorders**
Shirley Y. Hill, Sa Shen, Jeannette Locke, Stuart R. Steinhauer, Colleen Konicky, Lisa Lowers, and John Connolly

982 **Absence of Visual and Auditory P300 Reduction in Nondepressed Male and Female Alcoholics**
Shirley Y. Hill, Jeannette Locke, and Stuart R. Steinhauer

990 **Amphetamine Disrupts P50 Suppression in Normal Subjects**
Gregory A. Light, Dolores Malaspina, Mark A. Geyer, Bruce M. Luber, Eliza A. Coleman, Harold A. Sackeim, and David L. Braff

997 **Possible Association between Childhood Absence Epilepsy and the Gene Encoding GABRB3**
Martha Feucht, Karoline Fuchs, Ernest Pichlbauer, Kurt Hornik, Joachim Scharfetter, Ralph Goessler, Thomas Füreder, Nevenka Cvetkovic, Werner Sieghart, Siegfried Kasper, and Harald Aschauer

BRIEF REPORT

1003 **Spatial Working Memory: Absence of Gender Differences in Schizophrenia Patients and Healthy Control Subjects**
Kelly Minor and Sohee Park

Volume 46, Number 8, October 15, 1999

EDITORIALS

1007 **New Requirements for Manuscripts Submitted to *Biological Psychiatry*: Informed Consent and Protection of Subjects**
Dennis S. Charney, Robert B. Innis, and Eric J. Nestler

1009 **NIMH Symptom Challenge and Medication Discontinuation Workshop**
David Shore and Steven E. Hyman

COMMENTARIES

1011 **The National Bioethics Advisory Commission (NBAC) Report**
Eric M. Meslin

1013 **An NIMH Commentary on the NBAC Report**
David Shore and Steven E. Hyman

1017 **Medication Discontinuation and Symptom Provocation in Research: A Consumer and Family Perspective**
Laura Lee Hall

1021 **The Controversy over Challenge and Discontinuation Studies: Perspective from a Consumer-Psychiatrist**
Suzanne E. Vogel-Scibilia

REVIEWS

1025 **Psychiatric Research Ethics: An Overview of Evolving Guidelines and Current Ethical Dilemmas in the Study of Mental Illness**
Laura Weiss Roberts and Brian Roberts

1039 **IRB Review of Psychiatric Medication Discontinuation and Symptom-Provoking Studies**
Donald L. Rosenstein

1044 **Integrating Science and Ethics in Child and Adolescent Psychiatry Research**
Benedetto Vitiello, Peter S. Jensen, and Kimberly Hoagwood

1050 **Neuroleptic Discontinuation in Clinical and Research Settings: Scientific Issues and Ethical Dilemmas**
Dilip V. Jeste, Barton W. Palmer, and M. Jackuelyn Harris

1060 **Symptom Provocation Studies in Psychiatric Disorders: Scientific Value, Risks, and Future**
D. Cyril D'Souza, Robert M. Berman, John H. Krystal, and Dennis S. Charney

1081 **The Schizophrenia Ketamine Challenge Study Debate**
William T. Carpenter, Jr.

ORIGINAL ARTICLE

1092 **The Long-Term Effects of Placebo in Patients with Chronic Schizophrenia**
Richard Jed Wyatt, Ioline D. Henter, and John J. Bartko

TECHNIQUES AND METHODS

1106 **Ethical Dimensions of Psychiatric Research: A Constructive, Criterion-Based Approach to Protocol Preparation. The Research Protocol Ethics Assessment Tool (RePEAT)**
Laura Weiss Roberts

Volume 46, Number 9, November 1, 1999

EDITORIAL

1121 **New Vistas for an Old Neurotransmitter**
Ronald S. Duman and Dennis S. Charney

NOREPINEPHRINE: NEW VISTAS FOR AN OLD NEUROTRANSMITTER

1124 **Genetic Approaches to Studying Norepinephrine Function: Knockout of the Mouse Norepinephrine Transporter Gene**
Yan-Min Wang, Fei Xu, Raul R. Gainetdinov, and Marc G. Caron

1131 **Molecular Control of Locus Coeruleus Neurotransmission**
Eric J. Nestler, Meenakshi Alreja, and George K. Aghajanian

1140 **Role of Norepinephrine in Mediating Stress Hormone Regulation of Long-Term Memory Storage: A Critical Involvement of the Amygdala**
Barbara Ferry, Benno Roozendaal, and James L. McGaugh

1153 **The Role of Corticotropin-Releasing Factor–Norepinephrine Systems in Mediating the Effects of Early Experience on the Development of Behavioral and Endocrine Responses to Stress**
Darlene D. Francis, Christian Caldji, Frances Champagne, Paul M. Plotsky, and Michael J. Meaney

1167 **Corticotropin-Releasing Factor, Norepinephrine, and Stress**
George F. Koob

1181 **Neural Plasticity to Stress and Antidepressant Treatment**
Ronald S. Duman, Jessica Malberg, and Johannes Thome

1192 **Role of Norepinephrine in the Pathophysiology and Treatment of Posttraumatic Stress Disorder**
Steven M. Southwick, J. Douglas Bremner, Ann Rasmusson, Charles A. Morgan III, Amy Arnsten, and Dennis S. Charney

1205 **The Noradrenergic System in Pathological Anxiety: A Focus on Panic with Relevance to Generalized Anxiety and Phobias**
Gregory M. Sullivan, Jeremy D. Coplan, Justine M. Kent, and Jack M. Gorman

1219 **Role of Norepinephrine in the Pathophysiology and Treatment of Mood Disorders**
Kerry J. Ressler and Charles B. Nemeroff

1234 **Attention-Deficit/Hyperactivity Disorder (ADHD) as a Noradrenergic Disorder**
Joseph Biederman and Thomas Spencer

1243 **The Role of Norepinephrine in the Pathophysiology of Cognitive Disorders: Potential Applications to the Treatment of Cognitive Dysfunction in Schizophrenia and Alzheimer's Disease**
Joseph I. Friedman, David N. Adler, and Kenneth L. Davis

ORIGINAL ARTICLES

1253 **Plasma Norepinephrine and Prediction of Outcome in Major Depressive Disorder**
Timothy G. Johnston, Christopher B. Kelly, Michael R. Stevenson, and Stephen J. Cooper

1259 **Local Infusion of an α-1 Adrenergic Agonist into the Prefrontal Cortex Impairs Spatial Working Memory Performance in Monkeys**
Zheng-Mei Mao, Amy F.T. Arnsten, and Bao-Ming Li

1266 **A Role for Norepinephrine in Stress-Induced Cognitive Deficits: α-1-Adrenoceptor Mediation in the Prefrontal Cortex**
Shari Birnbaum, Kevin T. Gobeske, Joshua Auerbach, Jane R. Taylor, and Amy F.T. Arnsten

1275 **Elevated Levels of Tyrosine Hydroxylase in the Locus Coeruleus in Major Depression**
Meng-Yang Zhu, Violetta Klimek, Ginny E. Dilley, John W. Haycock, Craig Stockmeier, James C. Overholser, Herbert Y. Meltzer, and Gregory A. Ordway

1287 **Alpha-1-Noradrenergic Neurotransmission, Corticosterone, and Behavioral Depression**
Eric A. Stone and David Quartermain

REVIEWS

1301 **A Review of the Efficacy of Serotonergic and Noradrenergic Reuptake Inhibitors for Treatment of Major Depression**
J. Craig Nelson

1309 **Role of Locus Coeruleus in Attention and Behavioral Flexibility**
Gary Aston-Jones, Janusz Rajkowski, and Jonathan Cohen

Volume 46, Number 10, November 15, 1999

EDITORIAL

1321 **Treatment of Schizophrenia and Spectrum Disorders: Pharmacotherapy, Psychosocial Treatments, and Neurotransmitter Interactions**
Herbert Y. Meltzer

ZISKIND-SOMERFELD RESEARCH AWARD

1328 **Protein Kinase C Signaling in the Brain: Molecular Transduction of Mood Stabilization in the Treatment of Manic-Depressive Illness**
Husseini K. Manji and Robert H. Lenox

A.E. BENNETT RESEARCH AWARD

1352 **Anatomic Basis for Differential Regulation of the Rostrolateral Peri–Locus Coeruleus Region by Limbic Afferents**
Elisabeth J. Van Bockstaele, James Peoples, and Rita J. Valentino

PRIORITY COMMUNICATIONS

1364 **Baseline Cerebral Hypermetabolism Associated with Carbamazepine Response, and Hypometabolism with Nimodipine Response in Mood Disorders**
Terence A. Ketter, Tim A. Kimbrell, Mark S. George, Mark W. Willis, Brenda E. Benson, Aimee Danielson, Mark A. Frye, Peter Herscovitch, and Robert M. Post

1375 **PET Imaging of Serotonin 1A Receptor Binding in Depression**
Wayne C. Drevets, Ellen Frank, Julie C. Price, David J. Kupfer, Daniel Holt, Phil J. Greer, Yiyun Huang, Clara Gautier, and Chester Mathis

SCHIZOPHRENIA RESEARCH SERIES: TREATMENT

1388 **Neurotransmitter Interactions in Schizophrenia—Therapeutic Implications**
Arvid Carlsson, Nicholas Waters, and Maria L. Carlsson

1396 **Pharmacologic Treatment of Schizophrenia**
John M. Kane

1409 **A Critical Review of Research on Psychosocial Treatment of Schizophrenia**
John Lauriello, Juan Bustillo, and Samuel J. Keith

REVIEW

1418 **Childhood-Onset Schizophrenia: Rare but Worth Studying**
Rob Nicolson and Judith L. Rapoport

ORIGINAL ARTICLES

1429 **Olanzapine Safety and Efficacy in Patients with Borderline Personality Disorder and Comorbid Dysthymia**
S. Charles Schulz, Kelly L. Camlin, Sally A. Berry, and John A. Jesberger

1436 **Qualitative MRI Findings in Adults with 22q11 Deletion Syndrome and Schizophrenia**
Eva W.C. Chow, David J. Mikulis, Robert B. Zipursky, Laura E. Scutt, Rosanna Weksberg, and Anne S. Bassett

1443 **Selective α7 Nicotinic Receptor Stimulation Normalizes Chronic Cocaine-Induced Loss of Hippocampal Sensory Inhibition in C3H Mice**
Karen E. Stevens, William R. Kem, and Robert Freedman

BRIEF REPORT

1451 **Right Prefrontal Slow Repetitive Transcranial Magnetic Stimulation in Schizophrenia: A Double-Blind Sham-Controlled Pilot Study**
Ehud Klein, Yael Kolsky, Michael Puyerovsky, Danny Koren, Andrei Chistyakov, and Moshe Feinsod

1455 **Erratum**

Volume 46, Number 11, December 1, 1999

EDITORIAL

1457 **Development and Vulnerability: New Perspectives for Anxiety Disorders**
Stephen L. Foote

ROLE OF BIOLOGICAL AND PSYCHOLOGICAL FACTORS IN EARLY DEVELOPMENT AND THEIR IMPACT ON ADULT LIFE

1461 **Neural Circuits Mediating Stress**
Juan F. López, Huda Akil, and Stanley J. Watson

1472 **Stress and Hippocampal Neurogenesis**
Elizabeth Gould and Patima Tanapat

1480 **Corticotropin-Releasing Hormone Receptor Subtypes and Emotion**
Thomas Steckler and Florian Holsboer

1509 **The Impact of Early Adverse Experiences on Brain Systems Involved in the Pathophysiology of Anxiety and Affective Disorders**
Christine Heim and Charles B. Nemeroff

1523 **Vulnerability Factors among Children at Risk for Anxiety Disorders**
Kathleen Ries Merikangas, Shelli Avenevoli, Lisa Dierker, and Christian Grillon

1536 **Early Childhood Predictors of Adult Anxiety Disorders**
Jerome Kagan and Nancy Snidman

1542 **A Developmental Psychopathology Model of Childhood Traumatic Stress and Intersection with Anxiety Disorders**
Robert S. Pynoos, Alan M. Steinberg, and John C. Piacentini

1555 **Pathophysiology of Childhood Anxiety Disorders**
Daniel S. Pine

1567 **The Treatment of Anxiety Disorders in Children and Adolescents**
Michael J. Labellarte, Golda S. Ginsburg, John T. Walkup, and Mark A. Riddle

1579 **Current Treatments of the Anxiety Disorders in Adults**
James C. Ballenger

Volume 46, Number 12, December 15, 1999

PRIORITY COMMUNICATIONS

1595 **Decrease in Cortisol Reverses Human Hippocampal Atrophy following Treatment of Cushing's Disease**
Monica N. Starkman, Bruno Giordani, Stephen S. Gebarski, Stanley Berent, M. Anthony Schork, and David E. Schteingart

1603 **Frequency Dependence of Antidepressant Response to Left Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) as a Function of Baseline Cerebral Glucose Metabolism**
Timothy A. Kimbrell, John T. Little, Robert T. Dunn, Mark A. Frye, Benjamin D. Greenberg, Eric M. Wassermann, Jennifer D. Repella, Aimee L. Danielson, Mark W. Willis, Brenda E. Benson, Andrew M. Speer, Elizabeth Osuch, Mark S. George, and Robert M. Post

ORIGINAL ARTICLES

1614 **Amygdala Enlargement in Dysthymia—A Volumetric Study of Patients with Temporal Lobe Epilepsy**
Ludger Tebartz van Elst, Friedrich G. Woermann, Louis Lemieux, and Michael R. Trimble

1624 **Reciprocal Changes in Prefrontal and Limbic Dopamine Responsiveness to Aversive and Rewarding Stimuli after Chronic Mild Stress: Implications for the Psychobiology of Depression**
Gaetano Di Chiara, Patrizio Loddo, and Gianluigi Tanda

1634 **Effects of Lithium and Amphetamine on Inositol Metabolism in the Human Brain as Measured by ^{1}H and ^{31}P MRS**
Peter H. Silverstone, Susan Rotzinger, Andrew Pukhovsky, and Christopher C. Hanstock

1642 **Photopic and Scotopic Light Detection in Patients with Seasonal Affective Disorder and Control Subjects**
Jiuan Su Terman and Michael Terman

1649 **Interleukin-1β Production in Dysthymia before and after Pharmacotherapy**
Hymie Anisman, Arun V. Ravindran, Jenna Griffiths, and Zul Merali

1656 **Sensory Gating in Chronic Posttraumatic Stress Disorder: Reduced Auditory P50 Suppression in Combat Veterans**
Thomas C. Neylan, Daniel J. Fletcher, Maryann Lenoci, Keith McCallin, Daniel S. Weiss, Frank B. Schoenfeld, Charles R. Marmar, and George Fein

1665 **Opposite Changes in Phosphoinositide-Specific Phospholipase C Immunoreactivity in the Left Prefrontal and Superior Temporal Cortex of Patients with Chronic Schizophrenia**
Xian-Hao Lin, Noboru Kitamura, Takeshi Hashimoto, Osamu Shirakawa, and Kiyoshi Maeda

1672 **The Preventative Role of Antioxidants (Selegiline and Vitamin E) in a Rat Model of Tardive Dyskinesia**
Perminder Sachdev, Tanya Saharov, and Stuart Cathcart

1682 **Correlations of Glutathione Peroxidase Activity with Memory Impairment in Adults with Down Syndrome**
Karen Brugge, Sharon Nichols, Tsunao Saitoh, and Doris Trauner

1690 **Age-Related Changes in Quantitative EEG in Attention-Deficit/Hyperactivity Disorder**
Susan M. Bresnahan, John W. Anderson, and Robert J. Barry

1698 **Reduction of the Small Synaptic Vesicle Protein Synaptophysin but Not the Large Dense Core Chromogranins in the Left Thalamus of Subjects with Schizophrenia**
Mikael Landén, Pia Davidsson, Carl-Gerhard Gottfries, Bengt Grenfeldt, Mats Stridsberg, and Kaj Blennow

BRIEF REPORT

1703 **Decreased Serotonin Transporter Binding in Unaffected Relatives of Manic Depressive Patients**
Marion Leboyer, Philippe Quintin, Philippe Manivet, Odile Varoquaux, Jean-François Allilaire, and Jean-Marie Launay

CASE REPORT

1707 **Mania Associated with St. John's Wort**
Andrew A. Nierenberg, Tal Burt, John Matthews, and Anthony P. Weiss

CORRESPONDENCE

1709 **Behavioral, Neuroendocrine, and Cardiovascular Response to Flumazenil: No Evidence for an Altered Benzodiazepine Receptor Sensitivity in Panic Disorder**
John Potokar, Sue Wilson, David Nutt, and Chris Lawson

1711 **The Efficacy of Lamotrigine in Rapid Cycling and Non–Rapid Cycling Patients with Bipolar Disorder**
Robert M. Hamer and Pippa M. Simpson

1712 **Landmark Analysis of Corpus Callosum Shape in Schizophrenia**
John R. DeQuardo

1715 **Acknowledgments**

1718 **Author Index**

1728 **Subject Index**